Skip to content

Spyre Therapeutics, Inc. SYRE Acquired in-process research and development

Acquired in-process research and development at other companies

Campbell Soup logo
Campbell SoupCPB
$6M-82.9%
Cboe Global Markets logo
Cboe Global MarketsCBOE
$0-100%
Mid-America Apartment Communities logo
Mid-America Apartment CommunitiesMAA
$75.26M+13.6%
RBC Bearings logo
RBC BearingsRBC
$8.6M+4.2%
Eli Lilly logo
Eli LillyLLY
$584M-62.8%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$228.9M+1.6%

Other financials

Income statement

See full
Revenue-
Operating income-$45.6M+14.8%
Net income-$69.0M-54.1%
EPS (diluted)-$0.74-23.3%

Balance sheet

See full
Cash & equivalents$97.2M+100%
Total debt$4.3M-9.6%
Total equity$670.8M+39.0%
Total assets$764.0M+34.1%

Cash flow

See full
Operating cash flow-$57.4M-40.0%
CapEx-
Free cash flow-$39.4M-26.8%

Valuation

See full
Market cap$7.67B+307%

Profitability

See full
Operating margin-39,428.9%-49,795pp
Net margin-52,939.7%-61,871pp
FCF margin-3,442.8%-3,807pp

Returns & leverage

See full
Return on equity-31.1%-10.7pp
Debt / equity0.1×+0.1×
Current ratio+0.9×

Where this comes from

Reported directly by Spyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept syre:AcquiredInProcessResearchAndDevelopment.

The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Spyre Therapeutics, Inc.'s acquired in-process research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Spyre Therapeutics, Inc.'s acquired in-process research and development?
Spyre Therapeutics, Inc. (SYRE) reported acquired in-process research and development of $0 in Q1 2026.
What does acquired in-process research and development mean?
This represents the value assigned to research and development projects acquired through business combinations that have not yet reached technological feasibility. It is often expensed immediately upon acquisition, impacting net income without a corresponding cash outflow in the operating section if treated as a non-cash adjustment. It highlights the company's strategy for inorganic growth in its pipeline.